Toggle Main Menu Toggle Search

Open Access padlockePrints

Inflammation in Mild Cognitive Impairment due to Parkinson’s disease, Lewy Body disease and Alzheimer’s disease

Lookup NU author(s): Dr Rachael LawsonORCiD, Dr Christopher Morris, Nicola Barnett, Kirsty Olsen, Dr Alison Yarnall, Professor John-Paul TaylorORCiD, Dr Gordon Duncan



This is the authors' accepted manuscript of an article that has been published in its final definitive form by John Wiley & Sons Ltd., 2019.

For re-use rights please refer to the publisher's terms and conditions.


Background Inflammation appears to play a role in the progression of neurodegenerative diseases. However, little is known about inflammation during early stages of cognitive decline or whether this differs in different disease groups. We sought to investigate this by assessing the inflammatory profile in patients with Parkinson’s disease with the early stages of cognitive impairment (PD-MCI), patients with prodromal Alzheimer’s disease (MCI-AD), prodromal Lewy Body disease (MCI-LB) and controls. Methods We obtained venous blood samples from participants with PD-MCI (n = 44), PD-normal cognition (n112) MCI-LB (n = 38), MCI-AD (n = 21) and controls (n = 84). We measured 10 cytokines using Meso Scale Discovery V-Plex Plus including interferon-gamma, interleukin (IL)-10, IL-12p70, IL-13, IL-1beta, IL-2, IL-4, IL-6, IL-8 and tumour necrosis factor alpha. High-sensitivity C–reactive protein was measured. Results There was a higher level of inflammation in patients with MCI-AD and MCI-LB compared with controls. PD non-cognitively impaired had higher inflammatory markers than controls but there was no difference between PD-MCI and controls. There was a decrease in inflammatory markers with increasing motor severity based on the Unified Parkinson’s Disease Rating Scale. Conclusions Inflammation may be involved in the onset of cognitive decline in patients with MCI-AD and MCI-LB but appears to be less prominent PD-MCI albeit in a small data set. This suggests that anti-inflammatory medications may have most benefit at the earliest stages of neurodegenerative diseases. For PD cases, this might be in advance of the development of MCI.

Publication metadata

Author(s): King E, OBrien J, Donaghy P, WilliamsGray CH, Lawson RA, Morris CM, Barnett N, Olsen K, MartinRuiz C, Burn DJ, Yarnall AJ, Taylor JP, Duncan GW, Khoo TK, Thomas A

Publication type: Article

Publication status: Published

Journal: International Journal of Geriatric Psychiatry

Year: 2019

Volume: 34

Issue: 8

Pages: 1244-1250

Print publication date: 01/08/2019

Online publication date: 16/04/2019

Acceptance date: 05/04/2019

Date deposited: 11/04/2019

ISSN (print): 0885-6230

ISSN (electronic): 1099-1166

Publisher: John Wiley & Sons Ltd.


DOI: 10.1002/gps.5124

Notes: Inflammation, Mild cognitive impairment, Dementia, Parkinson’s disease, Alzheimer’s disease, Lewy body disease


Altmetrics provided by Altmetric


Funder referenceFunder name
J-0802Parkinson`s UK (formerly Parkinson`s Disease Society)